Neuraxpharm's ADHD Treatment, Paxneury, Receives EMA Approval, Accelerating Market Entry in Europe
A New Game Changer Emerges in the European ADHD Treatment Market
Neuraxpharm's Paxneury, an extended-release guanfacine-based ADHD treatment developed by its in-house R&D center, HealthTech, has received marketing authorization from the European Medicines Agency (EMA). This approval marks a significant milestone, as it represents the first generic and hybrid medicine containing extended-release guanfacine to be launched in the European Union (EU) market. With the entry of a competitively priced alternative to the existing market, which was previously dominated by Takeda's Intuniv, market competition is expected to intensify. Paxneury offers a safe and effective non-stimulant treatment option for children and adolescents aged 6 to 17 with ADHD who are not suitable for stimulant therapy or have poor tolerability to stimulants, making it clinically valuable.
Differentiated Market Positioning Through High-Dose Options
Paxneury has entered the market as a value-added medicine by attempting to diversify its formulation compared to the original medicine. By adding 5mg, 6mg, and 7mg extended-release tablets to its lineup, which were not previously available with Intuniv, Paxneury allows healthcare professionals to perform more flexible dose titration for individual patients. In clinical practice, it is often necessary to make small dose adjustments based on changes in the weight or symptom severity of pediatric and adolescent patients. Paxneury overcomes the previous inconvenience of having to take multiple tablets by providing a single-dose formulation. This improved ease of administration can improve medication adherence and lead to better long-term treatment outcomes.
Market Restructuring Based on the Collapse of Original Drug Monopoly and Price Competitiveness
This approval will be a turning point that will completely reshape the European ADHD treatment market, which is estimated to be worth approximately USD 3.71 billion annually by 2025. With its generic price competitiveness, Paxneury is likely to easily overcome the national prescription guideline barriers that previously restricted access to high-priced original medicines and achieve rapid market penetration. The price pressure resulting from the expansion of market share will put pressure on not only existing original drug manufacturers but also other therapeutic drug markets, such as methylphenidate. As a result, it will create a virtuous cycle that reduces the drug burden on patients while simultaneously improving the healthcare financial efficiency of each country.
Challenges in Price Negotiations and Reimbursement for Successful Commercialization Across Europe
Having overcome the biggest regulatory hurdle with EMA approval, Neuraxpharm now faces another challenge: price negotiations with national health authorities and reimbursement listing in each country. The European market has completely different healthcare financial systems and pharmacoeconomic evaluation criteria in each country, requiring a highly localized pricing policy and marketing strategy. Neuraxpharm plans to adopt a phased rollout strategy, starting with key markets and then expanding to surrounding countries. The specific level of insurance pricing agreements and reimbursement coverage with each government will be the final determinant of Paxneury's commercial success and maximum revenue.
The EMA approval of Paxneury, the first extended-release guanfacine generic/hybrid drug in Europe, is a significant short-term catalyst that will shake up the commercial landscape of the European ADHD market, which is worth approximately USD 3.71 billion annually. With its price competitiveness compared to Takeda's Intuniv and the provision of a unique high-dose portfolio of 5mg, 6mg, and 7mg, it is expected to facilitate prescription switching. In the medium to long term, it is expected to maximize the value of Neuraxpharm's CNS pipeline, which will have a positive impact on the exit valuation of Permira, its largest shareholder. However, in order to translate this into actual commercial revenue, it must overcome the individual price negotiation and reimbursement listing barriers with the health authorities of each European country. Therefore, the key investment indicators will be the future information on price agreements in major countries and the trend of prescription data.
Source: EMA (ema)